HealthTree

person Sign In / Create Account

Showing 202 trials matching your filters.

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple...

This is a single-arm, open-label phase II study with a safety lead-in phase.

DRUG: Bortezomib

DRUG: Isatuximab

DRUG: Cyclophosphamide

DRUG: Dexamethasone

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relap...

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. ...

DRUG: ABBV-453

DRUG: Dexamethasone

DRUG: Daratumumab

DRUG: Lenalidomide

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refrac...

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.

DRUG: AZD0305

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Mul...

The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin, nirogacestat, and pomalidomide is a safe treatment for people who have relapsed or refractory multiple myeloma. The researchers will tes...

DRUG: Belantamab Mafodotin

DRUG: Nirogacestat

DRUG: Pomalidomide

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating in...

DRUG: Selinexor

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying...

Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is e...

DRUG: Belantamab mafodotin

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (...

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * To assess th...

DRUG: Lenalidomide

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for t...

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will b...

DRUG: GPC-100

DRUG: Propranolol

DRUG: G-CSF

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

DRUG: BMS-986453

DRUG: Fludarabine

DRUG: Cyclophosphamide

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Car...

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.

DRUG: BGB-11417

DRUG: Dexamethasone

DRUG: Carfilzomib

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

DRUG: Talquetamab

DRUG: Carfilzomib

DRUG: Daratumumab SC

DRUG: Lenalidomide

DRUG: Pomalidomide

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene...

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous ...

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Cilta-cel

DRUG: Cyclophosphamide

DRUG: Fludarabine

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Aga...

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken fr...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Aldesleukin

BIOLOGICAL: Individual Patient TCR-Transduced PBL

DRUG: Pembrolizumab (KEYTRUDA )

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Mult...

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.

DRUG: OPN-6602

DRUG: Dexamethasone

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in...

Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.

DRUG: Belumosudil mesylate

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treat...

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatme...

DRUG: Linvoseltamab

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Lenalidomide

DRUG: Bortezomib

DRUG: Pomalidomide

DRUG: Isatuximab

DRUG: Fianlimab

DRUG: Cemiplimab

DRUG: Nirogacestat

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation...

The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after tran...

DRUG: Belantamab mafodotin

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnose...

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenali...

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Acetaminophen

DRUG: Diphenhydramine

DRUG: Montelukast

DRUG: Carfilzomib

DRUG: Daratumumab

BIOLOGICAL: Autologous Stem Cell Transplant (ASCT)

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) ...

The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population. The risk of such a study is deemed reasonable and ethic...

DRUG: Allopurinol

DRUG: Carmustine

DRUG: Etoposide

DRUG: Cytarabine

DRUG: Melphalan

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Recep...

This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA C...

DRUG: Radiation Therapy

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also ...

DRUG: Itacitinib

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multipl...

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Lenalidomide

DRUG: Dexamethasone

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent o...

This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC...

BIOLOGICAL: Autologous MUC1-activated T-cells

DRUG: Cyclophosphamide

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination Wi...

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

DRUG: CC-92480

DRUG: Tazemetostat

DRUG: BMS-986158

DRUG: Trametinib

DRUG: Dexamethasone

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bo...

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in ...

DRUG: Dexamethasone

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Iberdomide

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill t...

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

RADIATION: Radiation Therapy

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

DRUG: Cyclophosphamide

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Fludarabine

DRUG: Melphalan

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or L...

The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lena...

DRUG: Lenalidomide

DRUG: Daratumumab

BEHAVIORAL: Questionnaires

OTHER: Dietary Intervention

Ixazomib + Pomalidomide + Dexamethasone In MM

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

DRUG: Ixazomib

DRUG: Pomalidomide

DRUG: Dexamethasone

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the ...

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab and Hyaluronidase-fihj

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and...

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy ...

BIOLOGICAL: bb2121

DRUG: Lenalomide

DRUG: Talquetamab

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy D...

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexameth...

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Cilta-cel

DRUG: Cyclophosphamide

DRUG: Fludarabine

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based comb...

DRUG: Selinexor

DRUG: Pomalidomide

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Dexamethasone

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually ...

DRUG: Teclistamab

DRUG: Lenalidomide

DRUG: Dexamethasone

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it ...

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transpl...

DRUG: Linvoseltamab

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hemat...

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to eva...

DRUG: IDP-023

DRUG: Rituximab

DRUG: Daratumumab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

BIOLOGICAL: anitocabtagene-autoleucel

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual T...

This phase II trial compares the combination of selinexor, daratumumab, Velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-ri...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Bortezomib

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

DRUG: Daratumumab and Recombinant Human Hyaluronidase

DRUG: Dexamethasone

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

DRUG: Selinexor

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the imm...

DRUG: Isatuximab

OTHER: Standard Procedures

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory...

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multip...

BIOLOGICAL: Actinium Ac 225-DOTA-Daratumumab

BIOLOGICAL: Daratumumab

BIOLOGICAL: Indium In 111-DOTA-Daratumumab

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease ...

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

DRUG: Isatuximab

DRUG: Lenalidomide

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus de...

DRUG: Selinexor

DRUG: Dexamethasone Oral

DRUG: Daratumumab

DRUG: Lenalidomide

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Aut...

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

DRUG: Budesonide EC

DRUG: Placebo

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refract...

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better resu...

DRUG: Iberdomide

DRUG: Carfilzomib

DRUG: Daratumumab

DRUG: Dexamethasone

DRUG: Acetaminophen

DRUG: Diphenhydramine

DRUG: Montelukast

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usu...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Iberdomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Patient Monitoring

PROCEDURE: Positron Emission Tomography

PROCEDURE: Skeletal Survey X-Ray

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD...

This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not res...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Dexamethasone

PROCEDURE: Echocardiography

BIOLOGICAL: Elotuzumab

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mezigdomide

PROCEDURE: X-Ray Imaging

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodo...

BIOLOGICAL: Belantamab Mafodotin

DRUG: Dexamethasone

DRUG: Pomalidomide

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Tr...

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail ...

DRUG: Bortezomib

DRUG: Daratumumab and Hyaluronidase-fihj

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma...

To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

DRUG: Isatuximab

DRUG: lenalidomide

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.

DRUG: DaraVRD

A Study of Daratumumab

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab...

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity imp...

BEHAVIORAL: CHAMPS-II adapted to adults 60+ years in HCT setting

A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participan...

This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). DLBCL is ...

DRUG: EZM0414

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic...

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their can...

DRUG: Choline Salicylate

DRUG: Selinexor

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/...

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

DRUG: Cevostamab

DRUG: Tocilizumab

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple M...

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

DRUG: Selinexor

DRUG: Venetoclax

DRUG: Dexamethasone

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple...

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to stan...

DRUG: Belantamab mafodotin

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Dexamethasone

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory ...

This phase I/II trial studies the safety of the combination of bortezomib, dexamethasone, and pembrolizumab with or without pelareorep in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refract...

DRUG: Bortezomib

DRUG: Dexamethasone

BIOLOGICAL: Pelareorep

BIOLOGICAL: Pembrolizumab

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradi...

This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplant...

DRUG: Evomela

DRUG: Fludarabine

RADIATION: Total Body Irradiation

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudies 02, 03, and 06 are controlled experimental substudies. Substudi...

DRUG: Isatuximab

DRUG: Dexamethasone

DRUG: Pomalidomide

DRUG: Belantamab mafodotin

DRUG: Pegenzileukin

DRUG: SAR439459

DRUG: Belumosudil

DRUG: Evorpacept

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that ha...

DRUG: Isatuximab

DRUG: Pomalidomide

DRUG: Dexamethasone

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With ...

This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma p...

DRUG: Selinexor 60 MG

DRUG: Selinexor 80 MG

DRUG: Selinexor 100 MG

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Daratumumab

DRUG: Dexamethasone

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE ...

The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

DRUG: Teclistamab

DRUG: Talquetamab

DRUG: Daratumumab SC

The Ambient Light Multiple Myeloma Study

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cel...

DEVICE: Circadian Effective Lighting

DEVICE: Circadian Ineffective Lightning (CIL)

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With R...

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney f...

DRUG: ABBV-383

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with...

DRUG: KTX-1001

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezom...

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRM...

DRUG: mezigdomide

DRUG: Pomalidomide

DRUG: Bortezomib

DRUG: Dexamethasone

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Ca...

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

DRUG: Teclistamab

DRUG: Pomalidomide

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Carfilzomib

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the f...

DRUG: Iberdomide

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) ...

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolera...

DRUG: Elranatamab

DRUG: Carfilzomib

DRUG: Maplirpacept

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: * Cilta-cel (or ...

DRUG: Ciltacabtagene Autoleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

DRUG: Talquetamab

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell ...

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.

DRUG: Fludarabine phosphate

DRUG: Cyclophosphamide

DRUG: NY-ESO-1 TCR/IL-15 NK

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy ...

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidom...

DRUG: Lenalidomide

DRUG: Daratumumab/rHuPH20

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple My...

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells ...

DRUG: Dexamethasone

DRUG: Leflunomide

DRUG: Pomalidomide

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Mye...

This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide,...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Iberdomide

18F-Fluciclovine PET/CT in Multiple Myeloma

Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning di...

DRUG: 18F-fluciclovine injection

PROCEDURE: 18F-FDG PET/CT

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multi...

The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with I...

DRUG: Iberdomide

DRUG: Daratumumab/rHuPH20 Co-formulation

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

DRUG: HDP-101

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With...

The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

DRUG: Teclistamab (IV)

DRUG: Teclistamab(SC)

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

BIOLOGICAL: MCARH125

BIOLOGICAL: MCARH109

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune ...

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy f...

DRUG: Siltuximab

DARA RVD For High Risk SMM

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to a...

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulati...

DRUG: Carfilzomib

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Granulocyte Colony-Stimulating Factor

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases. While still considered an incurable disease, new treatments have improved outcomes dramatically over the last two decade...

DRUG: Mezigdomide

DRUG: Ixazomib

DRUG: Dexamethasone

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antige...

This is a multicenter phase II, open-label study evaluating the efficacy and safety of belantamab mafodotin maintenance in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received commercially available anti-BCMA CAR-T-c...

DRUG: Belantamab mafodotin

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion i...

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom M...

DRUG: Iopofosine I 131 single dose

DRUG: Iopofosine I 131 multiple dose

DRUG: Iopofosine I 131 fractionated dose

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following ...

BIOLOGICAL: Autologous CAR-T cell therapy expressing the BAFF-ligand.

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myelo...

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has co...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Computed Tomography

BIOLOGICAL: Mezigdomide

PROCEDURE: Positron Emission Tomography

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multi...

This phase I trial tests the side effects and best dose of TGFbi natural killer (NK) cells (TiNK) when given together with isatuximab for the treatment of patients with multiple myeloma that has come back after a period of improvement (relapsed) or t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Dexamethasone

PROCEDURE: Echocardiography

BIOLOGICAL: Isatuximab

OTHER: Questionnaire Administration

BIOLOGICAL: Universal Donor Expanded TGF-beta-imprinted NK Cells

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomal...

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone ...

DRUG: Talquetamab

DRUG: Pomalidomide

DRUG: Teclistamab

DRUG: Elotuzumab

DRUG: Dexamethasone

DRUG: Bortezomib

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Ris...

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune ...

DRUG: Dexamethasone

DRUG: Iberdomide Hydrochloride

OTHER: Quality-of-Life Assessment

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multip...

This phase I trial finds out the best dose and side effects of venetoclax and tocilizumab in treating patients with t(11;14) multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Venetoclax may stop the growth ...

BIOLOGICAL: Tocilizumab

DRUG: Venetoclax

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positi...

This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (...

PROCEDURE: CS1-CAR T Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple ...

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or...

DRUG: Elranatamab

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone

DRUG: Bortezomib

DRUG: Carfilzomib

Elranatamab in R/R Multiple Myeloma

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

DRUG: Elranatamab

Umbilical Cord Blood Transplantation From Unrelated Donors

This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

RADIATION: Total Body Irradiation 1200 cGy

RADIATION: Total Body Irradiation 200 cGy

DRUG: Cyclophosphamide

DRUG: Mesna

PROCEDURE: Cord Blood Infusion

DRUG: Busulfan

DRUG: Fludarabine

DRUG: Melphalan

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safet...

DRUG: Talquetamab

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments...

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phas...

DRUG: Belantamab mafodotin

DRUG: GSK3174998

DRUG: Feladilimab

DRUG: Nirogacestat

DRUG: Dostarlimab

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Pomalidomide

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

DRUG: OriCAR-017

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently sta...

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Dexamethasone

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory...

This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal anti...

DRUG: Carfilzomib

DRUG: Dexamethasone

BIOLOGICAL: Isatuximab

DRUG: Pomalidomide

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Skeletal Survey X-Ray

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing...

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that ma...

DRUG: Loratadine

OTHER: Placebo

OTHER: Questionnaire Administration

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance T...

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a subo...

BIOLOGICAL: idecabtagene vicleucel

DRUG: Lenalidomide

DRUG: Fludarabine

DRUG: Cyclophosphamide

Personalized Autologous Transplant for Multiple Myeloma

This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells,...

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

DRUG: Melphalan

OTHER: Questionnaire Administration

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients...

This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple myeloma that has come bac...

DRUG: Carfilzomib

DRUG: Dexamethasone

DRUG: Pomalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Selinexor

PROCEDURE: X-Ray Imaging

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell ...

Background: - In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called...

BIOLOGICAL: Rituximab

DRUG: Conditioning chemotherapy

DRUG: TMS

DRUG: FLAG

DRUG: EPOCH-F

PROCEDURE: Hematopoietic stem cell transplant

DRUG: Palifermin

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (...

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 in...

DRUG: Talquetamab

DRUG: Teclistamab

DRUG: PD-1 Inhibitor

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Mult...

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists o...

DRUG: APG-2575+ Pd

DRUG: APG-2575 + DRd

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Bortezomib Injection

DRUG: Dexamethasone

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractor...

This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or tha...

BIOLOGICAL: Belantamab Mafodotin

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

DRUG: Dose escalation: COM902 monotherapy.

COMBINATION_PRODUCT: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

DRUG: Cohort expansion: COM902 (RDFE) monotherapy.

DRUG: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

COMBINATION_PRODUCT: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CA...

DRUG: Talquetamab

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations...

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

DRUG: BMS-986393

DRUG: Alnuctamab

DRUG: Mezigdomide

DRUG: Iberdomide

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After...

To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.

DRUG: Belantamab mafodotin

DRUG: Lenalidomide

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Rel...

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and de...

DRUG: Cevostamab

DRUG: Tocilizumab

DRUG: Pomalidomide

DRUG: Daratumumab

DRUG: Dexamethasone

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referre...

DRUG: Descartes-15

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell ...

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

DRUG: JNJ-68284528

DRUG: Lenalidomide

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Dexamethasone

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomid...

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to...

DRUG: Linvoseltamab

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd ...

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.

DRUG: Carfilzomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Bortezomib

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for M...

This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following h...

DRUG: Belantamab mafodotin

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

DRUG: Tasquinimod

DRUG: IRd chemotherapy

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric...

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

DRUG: ISB 2001

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

DRUG: ISB 1442 SC injection escalating doses

DRUG: ISB 1442 SC injection at RP2D

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hem...

The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell tran...

BIOLOGICAL: Ide-cel (bb2121)

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Tria...

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways t...

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Carfilzomib

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

PROCEDURE: Multigated Acquisition Scan

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

BIOLOGICAL: P-BCMA-ALLO1 CAR-T cells

DRUG: Rimiducid

Elimination of Minimal Residual Disease After Transplant

This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Worki...

DRUG: Dexamethasone

DRUG: Isatuximab

DRUG: Lenalidomide

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Pat...

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been sh...

BEHAVIORAL: Behavioral Intervention

DRUG: Beta-Adrenergic Antagonist

DRUG: Propranolol

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

OTHER: Resistance Training

OTHER: Short-Term Fasting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or R...

This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and ...

DRUG: Carfilzomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

OTHER: Quality-of-Life Assessment

DRUG: Selinexor

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple ...

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the ef...

BIOLOGICAL: CB-011

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or ...

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Dexamethasone

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multipl...

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This...

DRUG: Daratumumab SC

DRUG: Clarithromycin

DRUG: Pomalidomide

DRUG: Dexamethasone

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Mult...

This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

BIOLOGICAL: GC012F

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-...

BIOLOGICAL: COVID-19 Vaccine

OTHER: Diagnostic Laboratory Biomarker Analysis

BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

High Dose Ascorbic Acid for Plasma Cell Disorders

This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.

OTHER: Ascorbate

DRUG: Melphalan

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple...

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

DRUG: Elotuzumab

DRUG: Belantamab mafodotin

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Mono...

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. ...

DRUG: Cyclophosphamide

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Daratumumab

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body...

DRUG: CAR138 T Cells

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory M...

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

BIOLOGICAL: STI-1492

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After T...

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplan...

DRUG: Elranatamab

DRUG: Lenalidomide

DRUG: Elranatamab

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to N...

DRUG: Ketorolac

DRUG: Normal saline

DRUG: Acetaminophen

DRUG: Oxycodone Acetaminophen

DRUG: Morphine

DRUG: Hydrocodone/Acetaminophen

DRUG: Oxycodone

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapie...

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatm...

DRUG: ABBV-383

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Elotuzumab

DRUG: Selinexor

DRUG: Bortezomib

DRUG: Dexamethasone

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard t...

DRUG: NMS-03597812

DRUG: NMS-03597812 + dexamethasone

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or P...

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

DRUG: Curcumin plus Piperine

TriPRIL CAR T Cells in Multiple Myeloma

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. ...

DRUG: TriPRIL CAR T Cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with mult...

DRUG: Romosozumab

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multip...

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. ...

DRUG: Pomalidomide

DRUG: Carfilzomib

DRUG: dexamethasone

DRUG: Daratumumab

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3014 dose to be tested in...

BIOLOGICAL: GEN3014

DRUG: Daratumumab

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multi...

The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufactur...

DRUG: Teclistamab

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ine...

DRUG: IGM-2644

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously T...

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected...

DRUG: JNJ-79635322

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemi...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

BIOLOGICAL: Ipilimumab

Outpatient Administration of Teclistamab for Multiple Myeloma

This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients

DRUG: Teclistamab

DRUG: Tocilizumab

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-3...

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd)...

DRUG: ABBV-383

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

DRUG: Nirogacestat

DRUG: Daratumumab

Cevostamab Following CAR T Cell Therapy for RRMM

This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed...

DRUG: Cevostamab

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Dise...

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

OTHER: Discontinue maintenance therapy SOC

Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethason...

This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating patients with multiple myelo...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Chest Radiography

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

PROCEDURE: Low Dose Computed Tomography of the Whole Body

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

PROCEDURE: X-Ray Imaging

OTHER: Questionnaire Administration

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smol...

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways ...

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple My...

This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dos...

COMBINATION_PRODUCT: CIML NK Cells plus KP1237 and low dose IL-2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific A...

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to ch...

DRUG: Palbociclib

DRUG: Sunitinib

DRUG: Temsirolimus

DRUG: Trastuzumab and Pertuzumab

DRUG: Vemurafenib and Cobimetinib

DRUG: Regorafenib

DRUG: Olaparib

DRUG: Pembrolizumab

DRUG: Nivolumab and Ipilimumab

DRUG: Abemaciclib

DRUG: Talazoparib

DRUG: Atezolizumab and PHESGO

DRUG: Atezolizumab and Talazoparib

DRUG: Entrectinib

DRUG: Larotrectinib

DRUG: Tucatinib plus Trastuzumab Subcutaneous (SC)

DRUG: Futibatinib

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.

DRUG: Hyperbaric oxygen

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Ca...

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

DRUG: Mezigdomide

DRUG: Carfilzomib

DRUG: Dexamethasone

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-E...

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

DRUG: Cevostamab

DRUG: Tocilizumab

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

DRUG: Iberdomide

DRUG: Daratumumab

DRUG: Dexamethasone

DRUG: Carfilzomib

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Der...

* This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study. * This Treatment Extensio...

DRUG: Isatuximab intravenous (IV)

DRUG: Cemiplimab (SAR439684)

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

DRUG: Isatuximab subcutaneous (SC)

DRUG: Carfilzomib

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Fu...

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants...

DRUG: Belantamab mafodotin

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Le...

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter \[NIS\]) with or without cyclophosphamide or ipilimumab and nivolumab ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and...

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in ...

DRUG: Talquetamab

DRUG: Daratumumab

DRUG: Pomalidomide

DRUG: Dexamethasone

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells see...

BIOLOGICAL: TAA-specific CTLs

BIOLOGICAL: TAA-specific CTLs- fixed dose

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (...

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

DRUG: Ruxolitinib Oral Tablet [Jakafi]

DRUG: Lenalidomide

DRUG: Methylprednisolone

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin...

This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study wil...

DRUG: Belantamab mafodotin

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractor...

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity ...

DRUG: Talquetamab

DRUG: Teclistamab

DRUG: Daratumumab

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refr...

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

BIOLOGICAL: BMS-986393

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple ...

This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, s...

DRUG: selinexor

DRUG: carfilzomib

DRUG: dexamethasone

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKAL...

Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. There is no standard treatment for the cancer at this time or the currently used treatments do not work completely in all...

BIOLOGICAL: Kappa CD28 T cells

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Ther...

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

DRUG: Selinexor

DRUG: Lenalidomide

DRUG: Methylprednisolone

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexametha...

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Ixazomib

CART-38 in Adult AML and MM Patients

This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patien...

DRUG: 3x10(6) CART-38 cellls

DRUG: 7x10(5) CART-38 cells

DRUG: 7x10(6) CART-38 cells

DRUG: 3x10(7) CART-38 cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

FT576 in Subjects With Multiple Myeloma

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.

DRUG: FT576 (Allogenic CAR NK cells with BCMA expression)

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Daratumumab

DRUG: Bendamustine

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma...

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myelo...

DRUG: CFT7455

DRUG: Dexamethasone Oral

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myelom...

This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists o...

DRUG: Isatuximab (for run-in portion)

DRUG: Isatuximab (for expansion)

DRUG: Pomalidomide

DRUG: Elotuzumab

DRUG: Dexamethasone

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic L...

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 pha...

DRUG: Linvoseltamab

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer c...

DRUG: Dara-VRd intensification, Dara-R maintenance

DRUG: AHCT intensification, Dara-R maintenance

DRUG: AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance

DRUG: AHCT intensification, Dara-R consolidation, Dara-R maintenance

DRUG: Dara-VRd induction

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Carfilzomib

DRUG: Dexamethasone

DRUG: Dexamethasone Sodium Phosphate

PROCEDURE: Echocardiography

DRUG: Lenalidomide

DRUG: Navtemadlin

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal...

This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin ...

BIOLOGICAL: Belantamab Mafodotin

DRUG: Lenalidomide

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomali...

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regime...

DRUG: Selinexor

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone Oral

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib

DRUG: Dabrafenib

DRUG: Trametinib

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Ce...

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maint...

DRUG: Iberdomide

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments...

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

DRUG: Elranatamab + Nirogacestat

DRUG: Elranatamab + lenalidomide + dexamethasone

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (...

DRUG: Belantamab mafodotin

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cance...

This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.

BIOLOGICAL: SENTI-202

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info